ALNY - Alnylam Pharmaceuticals, Inc.
[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial result
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington's Disease Network (.
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam's stock has plunged more than 40% this year, but the company's financials look great. Investors have been spooked by a guidance cut and a rival drug's clinical setback.
Curated Wealth Partners LLC decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 96.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,095 shares of the biopharmaceutical company's stock after selling 34,533 shares during the period.
First Citizens Bank and Trust Co. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,874 shares of the biopharmaceutical company's stock, valued at approximately $709,000. Several other hedge funds have also recently
[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the
Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis experienced two pipeline setbacks on the same day in July.
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Onconetix (NASDAQ: ONCO - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 93.0% of Alnylam Pharmaceuticals shares
LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of the federal securities laws.
BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.
LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,' a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play' aims to help people recognize the symptoms of ATTR-CM earlie.
Alnylam Pharmaceuticals, Inc. shares have fallen 18% amid concerns over its ATTR-CM franchise following AstraZeneca/Ionis trial failure. I see pessimism as understandable but overdone; nucresiran's superior TTR knockdown and trial design differences support a credible case for TRITON-CM success. Even if TRITON-CM fails, Amvuttra's first-line share gains and Alnylam's diverse pipeline mitigate downside risk.
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and the company's growth prospects appear to support their enthusiasm.
Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk. Analyst Recommendations This is a breakdown of current
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-three research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Alnylam Pharmaceuticals (NASDAQ: ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook. Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam's TTR franchise